Form 4: Theriva Biologics Director Acquires Stock Options

Director John J. Monahan acquired 25,000 stock options in Theriva Biologics, Inc.

Summary

• John J. Monahan, a director of Theriva Biologics, Inc. (TOVX), reported a transaction involving the acquisition of stock options.
• The transaction occurred on April 29, 2025, with the report filed on May 1, 2025.
• Monahan acquired 25,000 stock options with an exercise price of $1.4144.
• These options vest pro rata on a monthly basis over 12 months, beginning May 1, 2025, and expire on April 29, 2032.
• Following the transaction, Monahan directly owns 25,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Theriva Biologics, Stock Options, Director, Form 4, Beneficial Ownership, Monahan, TOVX